Načítá se...
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
BACKGROUND: Radium-223 dichloride is an alpha emitter approved for metastatic castration-resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic factors during radium-223-based therapy. PATIENTS AND METHODS: Patients with histologically confirmed progressive CRP...
Uloženo v:
| Vydáno v: | Onco Targets Ther |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6301292/ https://ncbi.nlm.nih.gov/pubmed/30588025 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S174206 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|